Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
JYNT Stock Forecast 2025-2026
$11.02
Current Price
$168.64M
Market Cap
Buy 3
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to JYNT Price Targets
+81.5%
To High Target of $20.00
+40.7%
To Median Target of $15.50
-4.7%
To Low Target of $10.50
JYNT Price Momentum
-11.5%
1 Week Change
+9.5%
1 Month Change
-21.1%
1 Year Change
+3.7%
Year-to-Date Change
-28.0%
From 52W High of $15.32
+15.0%
From 52W Low of $9.58
📊 TOP ANALYST CALLS
Did JYNT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Joint Corp is one of their latest high-conviction picks.
Latest JYNT Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, JYNT has a bullish consensus with a median price target of $15.50 (ranging from $10.50 to $20.00). Currently trading at $11.02, the median forecast implies a 40.7% upside. This outlook is supported by 3 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jeff Van Sinderen at B. Riley Securities, projecting a 81.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
JYNT Analyst Ratings
3
Buy
2
Hold
0
Sell
JYNT Price Target Range
Low
$10.50
Average
$15.50
High
$20.00
Current: $11.02
Latest JYNT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for JYNT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 9, 2025 | Lake Street | Ryan Meyers | Buy | Maintains | $16.00 |
| Nov 8, 2024 | Roth MKM | George Kelly | Buy | Maintains | $15.00 |
| May 6, 2024 | B. Riley Securities | Jeff Van Sinderen | Buy | Maintains | $20.00 |
| May 3, 2024 | Roth MKM | George Kelly | Buy | Reiterates | $16.00 |
| Sep 14, 2023 | Roth MKM | George Kelly | Buy | Maintains | $13.00 |
| Aug 11, 2023 | Maxim Group | Hold | Downgrade | $0.00 | |
| Aug 11, 2023 | Roth MKM | Buy | Maintains | $0.00 | |
| Mar 13, 2023 | DA Davidson | Linda Bolton Weiser | Neutral | Upgrade | $15.00 |
| Aug 8, 2022 | DA Davidson | Linda Bolton Weiser | Underperform | Maintains | $12.00 |
| Aug 5, 2022 | B. Riley Securities | Jeff Van Sinderen | Buy | Upgrade | $31.00 |
| Aug 5, 2022 | Maxim Group | Anthony Vendetti | Buy | Upgrade | $36.00 |
| May 10, 2022 | DA Davidson | Linda Bolton Weiser | Underperform | Downgrade | $13.00 |
| May 9, 2022 | DA Davidson | Linda Bolton Weiser | Underperform | Downgrade | $13.00 |
| May 6, 2022 | Craig-Hallum | Hold | Downgrade | $0.00 | |
| Feb 25, 2022 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $69.00 |
| Aug 9, 2021 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $128.00 |
| Aug 6, 2021 | Roth Capital | George Kelly | Buy | Maintains | $105.00 |
| Jun 28, 2021 | Roth Capital | George Kelly | Buy | Maintains | $100.00 |
| Jun 3, 2021 | Maxim Group | Hold | Downgrade | $0.00 | |
| May 10, 2021 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $65.00 |
The Joint Corp. (JYNT) Competitors
The following stocks are similar to Joint Corp based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
The Joint Corp. (JYNT) Financial Data
The Joint Corp. has a market capitalization of $168.64M with a P/E ratio of 66.0x. The company generates $52.79M in trailing twelve-month revenue with a -16.4% profit margin.
Revenue growth is +7.3% quarter-over-quarter, while maintaining an operating margin of -5.2% and return on equity of -7.1%.
Valuation Metrics
Market Cap
$168.64M
Enterprise Value
$148.99M
P/E Ratio
66.0x
PEG Ratio
27.6x
Price/Sales
3.2x
Growth & Margins
Revenue Growth (YoY)
+7.3%
Gross Margin
+77.3%
Operating Margin
-5.2%
Net Margin
-16.4%
EPS Growth
-15.4%
Financial Health
Cash/Price Ratio
+13.0%
Current Ratio
1.6x
Debt/Equity
11.3x
ROE
-7.1%
ROA
-1.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
The Joint Corp. (JYNT) Business Model
About The Joint Corp.
What They Do
Provides accessible chiropractic care through clinics.
Business Model
The company operates a franchise model, allowing it to expand its network of clinics and provide affordable chiropractic services without the need for insurance or appointments. Its subscription-based model creates consistent revenue streams while ensuring ongoing care for clients.
Additional Information
The Joint Corp. is recognized as an emerging leader in the chiropractic care sector, emphasizing convenience and customer-centric services. Its focus on holistic and preventive health solutions aligns with current consumer trends in the healthcare industry.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
443
CEO
Mr. Sanjiv Razdan
Country
United States
IPO Year
2014
Website
www.thejoint.comThe Joint Corp. (JYNT) Latest News & Analysis
Latest News
Quick Summary
The Joint Corp. (NASDAQ: JYNT) has appointed Scott J. as CFO. He brings 30 years of experience in restaurants, retail, and consumer packaged goods.
Why It Matters
The appointment of an experienced CFO signals strategic leadership, potentially improving financial performance and investor confidence in The Joint Corp.'s growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Joint Corp. (NASDAQ: JYNT) plans a $5 million stock repurchase program starting August 2025, as authorized by its board of directors.
Why It Matters
A stock repurchase program signals confidence in the company's financial health and can boost share prices, enhancing shareholder value and potentially attracting more investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A seasoned HR executive with experience in major companies like Kimberly-Clark and Tenet Healthcare is set to join the board, potentially enhancing governance and strategic direction.
Why It Matters
The appointment of a seasoned HR executive with extensive franchise and healthcare experience to the board could enhance corporate governance and strategic direction, potentially boosting investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Joint Corp. (NASDAQ: JYNT) has announced leadership updates aimed at enhancing its chiropractic care network and wellness franchise strategy as of May 22, 2025.
Why It Matters
The announcement of leadership changes at The Joint Corp. may impact investor sentiment and stock performance, as management plays a crucial role in strategic direction and operational success.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
JYNT plans to open 30-40 franchised clinics in 2025, a decrease from 57 clinics opened last year.
Why It Matters
JYNT's reduced clinic opening forecast signals potential growth slowdown, impacting future revenue and investor sentiment. Lower expansion could signal operational challenges.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
The Joint Corp. (NASDAQ:JYNT) will host its Q1 2025 earnings conference call on May 8, 2025, at 5:00 PM ET, featuring key executives and analysts from various financial firms.
Why It Matters
The earnings call for The Joint Corp. will provide insights into Q1 2025 performance, influencing stock valuation and investor sentiment based on financial results and future guidance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About JYNT Stock
What is The Joint Corp.'s (JYNT) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, The Joint Corp. (JYNT) has a median price target of $15.50. The highest price target is $20.00 and the lowest is $10.50.
Is JYNT stock a good investment in 2025?
According to current analyst ratings, JYNT has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for JYNT stock?
Wall Street analysts predict JYNT stock could reach $15.50 in the next 12 months. This represents a 40.7% increase from the current price of $11.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is The Joint Corp.'s business model?
The company operates a franchise model, allowing it to expand its network of clinics and provide affordable chiropractic services without the need for insurance or appointments. Its subscription-based model creates consistent revenue streams while ensuring ongoing care for clients.
What is the highest forecasted price for JYNT The Joint Corp.?
The highest price target for JYNT is $20.00 from Jeff Van Sinderen at B. Riley Securities, which represents a 81.5% increase from the current price of $11.02.
What is the lowest forecasted price for JYNT The Joint Corp.?
The lowest price target for JYNT is $10.50 from at , which represents a -4.7% decrease from the current price of $11.02.
What is the overall JYNT consensus from analysts for The Joint Corp.?
The overall analyst consensus for JYNT is bullish. Out of 6 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $15.50.
How accurate are JYNT stock price projections?
Stock price projections, including those for The Joint Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 11:24 PM UTC